~~<i id='59315C00AB'><strike id='59315C00AB'><tt id='59315C00AB'><pre id='59315C00AB'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：focus 2025-09-06 05:50:52 Page View：24

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How dance can help nurses traumatized by Covid
Next article： As demand for Covid shots wanes, Moderna seeks its next success

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Impact of Dobbs ruling felt at reproductive medicine meeting

MathieuLewis-Rolland/GettyImagesNEWORLEANS—TheannualmeetingoftheAmericanSocietyofReproductiveMedicin

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Google and Epic fight stronger regulation of AI in health care

AdobeBigbusinessespoisedtoprofitfromtheadvanceofartificialintelligenceinhealthcarearepushingbackagai